Metabolic Comparison

CT-388 vs MariTide

Comparison of CT-388 (Moderate evidence) and MariTide (Moderate evidence).

Last updated: February 12, 2026

CT-388

Moderate Evidence
View full dossier

MariTide

Moderate Evidence
View full dossier

Overview

CT-388 and MariTide are both studied in the peptide research space.

CT-388: A dual GLP-1/GIP receptor agonist acquired by Roche through the $2.

MariTide: A bispecific peptide-antibody conjugate combining GLP-1 receptor agonism with GIP receptor antagonism.

Evidence Comparison

AspectCT-388MariTide
Evidence LevelModerateModerate
Human Studies612
Preclinical Studies22
Total Sources814

Key Differences

AspectCT-388MariTide
CategoryMetabolicMetabolic
Evidence StrengthModerateModerate
Total Sources814
Human Studies612

Summary

  • CT-388: Moderate evidence with 8 total sources (6 human)
  • MariTide: Moderate evidence with 14 total sources (12 human)

This comparison is for educational purposes only and is not medical advice. Consult a healthcare professional before making any decisions about peptide use.

Stay Updated on Peptide Comparisons

Get notified when we publish new comparison dossiers and evidence reviews.

No spam. Unsubscribe anytime.

Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.